Targeting BRAF-mutant colorectal cancer: Progress in combination strategies

Raghav Sundar; David S. Hong; Scott Kopetz; Timothy A. Yap

doi:10.1158/2159-8290.CD-17-0087

Targeting BRAF-mutant colorectal cancer: Progress in combination strategies

Raghav Sundar, David S. Hong, Scott Kopetz, Timothy A. Yap

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival.

Original language	English (US)
Pages (from-to)	558-560
Number of pages	3
Journal	Cancer discovery
Volume	7
Issue number	6
DOIs	https://doi.org/10.1158/2159-8290.CD-17-0087
State	Published - 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-17-0087

Cite this

@article{6725200146b140e0949a6c6ad26965ea,

title = "Targeting BRAF-mutant colorectal cancer: Progress in combination strategies",

abstract = "BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival.",

author = "Raghav Sundar and Hong, {David S.} and Scott Kopetz and Yap, {Timothy A.}",

note = "Publisher Copyright: {\textcopyright} 2017 AACR.",

year = "2017",

doi = "10.1158/2159-8290.CD-17-0087",

language = "English (US)",

volume = "7",

pages = "558--560",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Targeting BRAF-mutant colorectal cancer

T2 - Progress in combination strategies

AU - Sundar, Raghav

AU - Hong, David S.

AU - Kopetz, Scott

AU - Yap, Timothy A.

PY - 2017

Y1 - 2017

N2 - BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival.

AB - BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival.

UR - http://www.scopus.com/inward/record.url?scp=85020442626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020442626&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-17-0087

DO - 10.1158/2159-8290.CD-17-0087

M3 - Article

C2 - 28576843

AN - SCOPUS:85020442626

SN - 2159-8274

VL - 7

SP - 558

EP - 560

JO - Cancer discovery

JF - Cancer discovery

IS - 6

ER -

Targeting BRAF-mutant colorectal cancer: Progress in combination strategies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this